Patents by Inventor Nicolas Jacques Francois Dreyfus

Nicolas Jacques Francois Dreyfus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2,3-dihydrofuro[2,3-b]pyridine compounds
    Patent number: 11214576
    Abstract: The present invention provides a compound of Formula I: wherein R is H or F; or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treatment of neurodegenerative diseases, such as Alzheimer's disease.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: January 4, 2022
    Assignee: Eli Lilly and Company
    Inventors: Nicolas Jacques Francois Dreyfus, Andrew Faller
  • 5-METHYL-4-FLUORO-THIAZOL-2-YL COMPOUNDS
    Publication number: 20210323958
    Abstract: The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating neurodegenerative diseases, such as Alzheimers disease.
    Type: Application
    Filed: July 24, 2019
    Publication date: October 21, 2021
    Inventors: Nicolas Jacques Francois DREYFUS, Peter James LINDSAY-SCOTT
  • 2,3-DIHYDROFURO[2,3-B]PYRIDINE COMPOUNDS
    Publication number: 20210070766
    Abstract: The present invention provides a compound of Formula I: wherein R is H or F; or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treatment of neurodegenerative diseases, such as Alzheimer's disease.
    Type: Application
    Filed: June 14, 2019
    Publication date: March 11, 2021
    Inventors: Nicolas Jacques Francois DREYFUS, Andrew FALLER
  • 6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds
    Patent number: 10836773
    Abstract: The present invention provides a compound of Formula I: wherein R is hydrogen or methyl; and Z is: or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating neurodegenerative diseases, such as Alzheimer's disease.
    Type: Grant
    Filed: July 28, 2020
    Date of Patent: November 17, 2020
    Assignee: Eli Lilly and Company
    Inventors: Nicolas Jacques Francois Dreyfus, Jose Eduardo Lopez, Leonard Larry Winneroski, Jr., Eric Michael Woerly
  • 6-Fluoro-2-Methylbenzo[d]thiazol-5-yl Compounds
    Publication number: 20200354370
    Abstract: The present invention provides a compound of Formula I: wherein R is hydrogen or methyl; and Z is: or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating neurodegenerative diseases, such as Alzheimer's disease.
    Type: Application
    Filed: July 28, 2020
    Publication date: November 12, 2020
    Inventors: Nicolas Jacques Francois Dreyfus, Jose Eduardo Lopez, Leonard Larry Winneroski, JR., Eric Michael Woerly
  • 6-fluoro 2-methylbenzo[d]thiazol-5-yl compounds
    Patent number: 10752632
    Abstract: The present invention provides a compound of Formula I: wherein R is hydrogen or methyl; and Z is: or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating neurodegenerative diseases, such as Alzheimer's disease.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: August 25, 2020
    Assignee: Eli Lilly and Company
    Inventors: Nicolas Jacques Francois Dreyfus, Jose Eduardo Lopez, Leonard Larry Winneroski, Jr., Eric Michael Woerly
  • 6-Fluoro-2-Methylbenzo[d]thiazol-5-yl Compounds
    Publication number: 20200095254
    Abstract: The present invention provides a compound of Formula I: wherein R is hydrogen or methyl; and Z is: or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating neurodegenerative diseases, such as Alzheimer's disease.
    Type: Application
    Filed: September 19, 2019
    Publication date: March 26, 2020
    Inventors: Nicolas Jacques Francois Dreyfus, Jose Eduardo Lopez, Leonard Larry Winneroski, JR., Eric Michael Woerly
  • 5-methyl-1,3,4-oxadiazol-2-yl compounds
    Patent number: 10377750
    Abstract: The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treatment of neurodegenerative diseases and disorders, such as Alzheimer's disease.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: August 13, 2019
    Assignee: Eli Lilly and Company
    Inventors: Nicolas Jacques Francois Dreyfus, Peter James Lindsay-Scott, Richard Edmund Rathmell
  • 5-METHYL-1,3,4-OXADIAZOL-2-YL COMPOUNDS
    Publication number: 20180339984
    Abstract: The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treatment of neurodegenerative diseases and disorders, such as Alzheimer's disease.
    Type: Application
    Filed: May 18, 2018
    Publication date: November 29, 2018
    Inventors: Nicolas Jacques Francois Dreyfus, Peter James Lindsay-Scott, Richard Edmund Rathmell
  • 5-methyl-1,2,4-oxadiazol-3-yl compounds
    Patent number: 10081625
    Abstract: The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treatment of neurodegenerative diseases and disorders, such as Alzheimer's disease.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: September 25, 2018
    Assignee: Eli Lilly and Company
    Inventors: Nicolas Jacques Francois Dreyfus, Peter James Lindsay-Scott
  • 5-METHYL-1,2,4-OXADIAZOL-3-YL COMPOUNDS
    Publication number: 20180215751
    Abstract: The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treatment of neurodegenerative diseases and disorders, such as Alzheimer's disease.
    Type: Application
    Filed: January 19, 2018
    Publication date: August 2, 2018
    Applicant: Eli Lilly and Company
    Inventors: Nicolas Jacques Francois Dreyfus, Peter James Lindsay-Scott
  • Serotonin and norepinephrine reuptake inhibitor
    Patent number: 8173821
    Abstract: A serotonin and norepinephrine reuptake inhibitor of the formula: its uses, and methods for its preparation are described.
    Type: Grant
    Filed: April 6, 2010
    Date of Patent: May 8, 2012
    Assignee: Eli Lilly and Company
    Inventors: Nicolas Jacques Francois Dreyfus, Sandra Ann Filla, Anette Margareta Johansson, Thierry J. Masquelin, Jikesh Arvind Shah, Eric George Tromiczak, Magnus Wilhelm Walter
  • SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR
    Publication number: 20100261762
    Abstract: A serotonin and norepinephrine reuptake inhibitor of the formula: its uses, and methods for its preparation are described.
    Type: Application
    Filed: April 6, 2010
    Publication date: October 14, 2010
    Applicant: Eli Lilly and Company
    Inventors: Nicolas Jacques Francois DREYFUS, Sandra Ann FILLA, Anette Margareta JOHANSSON, Thierry J. MASQUELIN, Jikesh Arvind SHAH, Eric George TROMICZAK, Magnus Wilhelm WALTER